Publication:
Mortality-lowering effect of systemic corticosteroid therapy in severe tetanus

dc.contributor.authorsPaydaş, S.; Akoğlu, T. F.; Akkiz, H.; Ozer, F. L.; Burgut, R.
dc.date.accessioned2022-03-28T12:45:53Z
dc.date.accessioned2026-01-11T18:18:55Z
dc.date.available2022-03-28T12:45:53Z
dc.date.issued1988
dc.description.abstractIn a double-blind therapeutic trial, 32 patients suffering from severe tetanus were given prednisolone and 31 a placebo in addition to standard treatment. Mortality was lower in the prednisolone-treated group (31%) than in the placebo-treated group (55%). The women had more severe symptoms and a higher mortality than the men. The results suggest that the addition of a corticosteroid to standard treatment will lower mortality in tetanus, although meticulous nursing care is still the most important factor in treatment.
dc.identifier.issn0149-2918
dc.identifier.pubmedPMID: 3078907
dc.identifier.urihttps://hdl.handle.net/11424/255042
dc.language.isoeng
dc.relation.ispartofClinical Therapeutics
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectAdult
dc.subjectFemale
dc.subjectHumans
dc.subjectMiddle Aged
dc.subjectAged
dc.subjectAdolescent
dc.subjectMale
dc.subjectDouble-Blind Method
dc.subjectAdrenal Cortex Hormones
dc.subjectPrednisolone
dc.subjectRandomized Controlled Trials as Topic
dc.subjectTetanus
dc.subjectTetanus Antitoxin
dc.titleMortality-lowering effect of systemic corticosteroid therapy in severe tetanus
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage280
oaire.citation.startPage276
oaire.citation.titleClinical Therapeutics
oaire.citation.volume3

Files